EBV Specific T-Lymphocytes
Cell therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2021 (NCT04664179)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- epstein-barr virusImmunity, passive
epstein-barr virus immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06027879 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2024 | University of Pittsburgh |
| NCT05532826 | N/A | Sep 15, 2022 | Capital Medical University |
| NCT04664179 | Phase 1 | May 1, 2021 | Baylor University, The University of Texas, Dallas |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1